DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 16350.0
(-1.57%)
KRW 16350.0
(-1.57%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 338.16 Billion KRW | 11.63% |
| 2022 | 302.93 Billion KRW | 7.13% |
| 2021 | 282.77 Billion KRW | 12.48% |
| 2020 | 251.4 Billion KRW | 14.8% |
| 2019 | 219 Billion KRW | 20.47% |
| 2018 | 181.79 Billion KRW | 14.51% |
| 2017 | 158.76 Billion KRW | 17.08% |
| 2016 | 135.6 Billion KRW | 18.57% |
| 2015 | 114.36 Billion KRW | 14.13% |
| 2014 | 100.2 Billion KRW | 2.59% |
| 2013 | 97.67 Billion KRW | 25.34% |
| 2012 | 77.92 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 91.75 Billion KRW | 4.71% |
| 2024 Q1 | 87.62 Billion KRW | 5.99% |
| 2023 Q2 | 89.89 Billion KRW | 10.94% |
| 2023 FY | 338.16 Billion KRW | 11.63% |
| 2023 Q4 | 82.67 Billion KRW | -2.25% |
| 2023 Q3 | 84.56 Billion KRW | -5.93% |
| 2023 Q1 | 81.03 Billion KRW | 7.59% |
| 2022 Q4 | 75.31 Billion KRW | -5.16% |
| 2022 Q3 | 79.4 Billion KRW | 3.4% |
| 2022 Q2 | 76.79 Billion KRW | 7.52% |
| 2022 Q1 | 71.42 Billion KRW | -0.18% |
| 2022 FY | 302.93 Billion KRW | 7.13% |
| 2021 Q2 | 74.06 Billion KRW | 12.5% |
| 2021 Q1 | 65.83 Billion KRW | -5.77% |
| 2021 Q4 | 71.55 Billion KRW | 0.33% |
| 2021 Q3 | 71.32 Billion KRW | -3.7% |
| 2021 FY | 282.77 Billion KRW | 12.48% |
| 2020 Q2 | 66.16 Billion KRW | 15.08% |
| 2020 Q4 | 69.86 Billion KRW | 8.35% |
| 2020 FY | 251.4 Billion KRW | 14.8% |
| 2020 Q1 | 57.49 Billion KRW | 3.17% |
| 2020 Q3 | 64.48 Billion KRW | -2.54% |
| 2019 Q2 | 56.04 Billion KRW | 10.4% |
| 2019 FY | 219 Billion KRW | 20.47% |
| 2019 Q1 | 50.76 Billion KRW | 20.25% |
| 2019 Q4 | 55.72 Billion KRW | 3.08% |
| 2019 Q3 | 54.06 Billion KRW | -3.54% |
| 2018 Q2 | 46.74 Billion KRW | 13.76% |
| 2018 Q4 | 42.21 Billion KRW | -8.25% |
| 2018 Q3 | 46.01 Billion KRW | -1.56% |
| 2018 FY | 181.79 Billion KRW | 14.51% |
| 2018 Q1 | 41.09 Billion KRW | 9.72% |
| 2017 Q1 | 37.82 Billion KRW | 21.6% |
| 2017 Q4 | 37.44 Billion KRW | -8.2% |
| 2017 Q3 | 40.79 Billion KRW | -1.54% |
| 2017 Q2 | 41.42 Billion KRW | 9.52% |
| 2017 FY | 158.76 Billion KRW | 17.08% |
| 2016 FY | 135.6 Billion KRW | 18.57% |
| 2016 Q2 | 34.49 Billion KRW | 6.83% |
| 2016 Q1 | 32.29 Billion KRW | 9.08% |
| 2016 Q4 | 31.1 Billion KRW | -0.93% |
| 2016 Q3 | 31.39 Billion KRW | -8.98% |
| 2015 Q2 | 28.51 Billion KRW | 15.66% |
| 2015 Q1 | 24.65 Billion KRW | -6.4% |
| 2015 Q3 | 29.32 Billion KRW | 2.82% |
| 2015 Q4 | 29.6 Billion KRW | 0.96% |
| 2015 FY | 114.36 Billion KRW | 14.13% |
| 2014 Q3 | 24.82 Billion KRW | -5.76% |
| 2014 Q4 | 26.34 Billion KRW | 6.12% |
| 2014 FY | 100.2 Billion KRW | 2.59% |
| 2014 Q1 | 22.7 Billion KRW | -15.15% |
| 2014 Q2 | 26.34 Billion KRW | 16.04% |
| 2013 Q4 | 26.75 Billion KRW | 22.3% |
| 2013 FY | 97.67 Billion KRW | 25.34% |
| 2013 Q1 | 22.49 Billion KRW | 11.42% |
| 2013 Q2 | 26.55 Billion KRW | 18.09% |
| 2013 Q3 | 21.87 Billion KRW | -17.64% |
| 2012 FY | 77.92 Billion KRW | 0.0% |
| 2012 Q4 | 20.18 Billion KRW | 3.46% |
| 2012 Q3 | 19.51 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | -229.833% |
| CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | -793.055% |
| Celltrion Pharm, Inc. | 80.93 Billion KRW | -317.82% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | -14.681% |
| Enzychem Lifesciences Corporation | 18.7 Billion KRW | -1707.976% |
| Humedix Co., Ltd. | 33.04 Billion KRW | -923.403% |
| Boditech Med Inc. | 47.05 Billion KRW | -618.713% |
| EuBiologics Co., Ltd. | 24.95 Billion KRW | -1254.845% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -3589.317% |
| Huons Co., Ltd. | 226.14 Billion KRW | -49.536% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | -1241.995% |
| AptaBio Therapeutics Inc. | 16.45 Billion KRW | -1955.485% |